Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Operating Leases (2022 - 2025)

Historic Operating Leases for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to $48.0 million.

  • Entrada Therapeutics' Operating Leases fell 1031.43% to $48.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.0 million, marking a year-over-year decrease of 1031.43%. This contributed to the annual value of $51.6 million for FY2024, which is 1437.81% down from last year.
  • According to the latest figures from Q3 2025, Entrada Therapeutics' Operating Leases is $48.0 million, which was down 1031.43% from $49.3 million recorded in Q2 2025.
  • In the past 5 years, Entrada Therapeutics' Operating Leases registered a high of $73.0 million during Q2 2023, and its lowest value of $16.2 million during Q1 2023.
  • Over the past 4 years, Entrada Therapeutics' median Operating Leases value was $50.5 million (recorded in 2025), while the average stood at $46.2 million.
  • In the last 5 years, Entrada Therapeutics' Operating Leases tumbled by 4906.77% in 2023 and then skyrocketed by 25828.04% in 2024.
  • Quarter analysis of 4 years shows Entrada Therapeutics' Operating Leases stood at $17.5 million in 2022, then surged by 244.1% to $60.3 million in 2023, then dropped by 14.38% to $51.6 million in 2024, then decreased by 6.97% to $48.0 million in 2025.
  • Its Operating Leases stands at $48.0 million for Q3 2025, versus $49.3 million for Q2 2025 and $50.5 million for Q1 2025.